|
1
|
Avigan D and Rosenblatt J: Current
treatment for multiple myeloma. N Engl J Med. 371:961–962. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kumar SK, Rajkumar SV, Dispenzieri A, Lacy
MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust
JA, et al: Improved survival in multiple myeloma and the impact of
novel therapies. Blood. 111:2516–2520. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Richardson PG, Blood E, Mitsiades CS,
Jagannath S, Zeldenrust SR, Alsina M, Schlossman RL, Rajkumar SV,
Desikan KR, Hideshima T, et al: A randomized phase 2 study of
lenalidomide therapy for patients with relapsed or relapsed and
refractory multiple myeloma. Blood. 108:3458–3464. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kortuem KM, Zidich K, Schuster SR, Khan
ML, Jimenez-Zepeda VH, Mikhael JR, Fonseca R and Stewart AK:
Activity of 129 single-agent drugs in 228 Phase I and II clinical
trials in multiple myeloma. Clin Lymphoma Myeloma Leuk.
14:284–290.e5. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Quach H, Ritchie D, Stewart AK, Neeson P,
Harrison S, Smyth MJ and Prince HM: Mechanism of action of
immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia.
24:22–32. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ito T, Ando H, Suzuki T, Ogura T, Hotta K,
Imamura Y, Yamaguchi Y and Handa H: Identification of a primary
target of thalidomide teratogenicity. Science. 327:1345–1350. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhu YX, Braggio E, Shi CX, Bruins LA,
Schmidt JE, Van Wier S, Chang XB, Bjorklund CC, Fonseca R,
Bergsagel PL, et al: Cereblon expression is required for the
antimyeloma activity of lenalidomide and pomalidomide. Blood.
118:4771–4779. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Douer D and Tallman MS: Arsenic trioxide:
New clinical experience with an old medication in hematologic
malignancies. J Clin Oncol. 23:2396–2410. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM,
Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, et al: Use of arsenic
trioxide (As2O3) in the treatment of acute promyelocytic leukemia
(APL): II. Clinical efficacy and pharmacokinetics in relapsed
patients. Blood. 89:3354–3360. 1997.PubMed/NCBI
|
|
10
|
Soignet SL, Maslak P, Wang ZG, Jhanwar S,
Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J,
Scheinberg DA, et al: Complete remission after treatment of acute
promyelocytic leukemia with arsenic trioxide. N Engl J Med.
339:1341–1348. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Miller WH Jr, Schipper HM, Lee JS, Singer
J and Waxman S: Mechanisms of action of arsenic trioxide. Cancer
Res. 62:3893–3903. 2002.PubMed/NCBI
|
|
12
|
Chou TC: Theoretical basis, experimental
design, and computerized simulation of synergism and antagonism in
drug combination studies. Pharmacol Rev. 58:621–681. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lu G, Middleton RE, Sun H, Naniong M, Ott
CJ, Mitsiades CS, Wong KK, Bradner JE and Kaelin WG Jr: The myeloma
drug lenalidomide promotes the cereblon-dependent destruction of
Ikaros proteins. Science. 343:305–309. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bergsagel PL and Kuehl WM: Molecular
pathogenesis and a consequent classification of multiple myeloma. J
Clin Oncol. 23:6333–6338. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Krönke J, Udeshi ND, Narla A, Grauman P,
Hurst SN, McConkey M, Svinkina T, Heckl D, Comer E, Li X, et al:
Lenalidomide causes selective degradation of IKZF1 and IKZF3 in
multiple myeloma cells. Science. 343:301–305. 2014. View Article : Google Scholar : PubMed/NCBI
|
